Beyond the Glycaemic Control of Dapagliflozin: Microangiopathy and Non-classical Complications

Dapagliflozin is a selective sodium-glucose cotransporter 2 inhibitor (SGLT2i) indicated for the treatment of type 2 diabetes mellitus (T2DM), heart failure (HF) with reduced ejection fraction (EF) and chronic kidney disease (CKD). In monotherapy or as an additive therapy, dapagliflozin aids glycaem...

Descripción completa

Detalles Bibliográficos
Autores principales: Bellido, Virginia, Martínez, Julia, Calvo, Fernando, Villarroel, Aida, Lecumberri, Edurne, Moreno, Juan, Morillas, Carlos, Rodrigo, Silvia, Izarra, Aitziber, Lecube, Albert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9076778/
https://www.ncbi.nlm.nih.gov/pubmed/35338446
http://dx.doi.org/10.1007/s13300-022-01237-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9076778/
https://www.ncbi.nlm.nih.gov/pubmed/35338446
http://dx.doi.org/10.1007/s13300-022-01237-9

Ejemplares similares